CL2015001900A1 - Vacunas con mayor densidad de antigeno carbohidrato y nuevo adyuvante de saponina. - Google Patents

Vacunas con mayor densidad de antigeno carbohidrato y nuevo adyuvante de saponina.

Info

Publication number
CL2015001900A1
CL2015001900A1 CL2015001900A CL2015001900A CL2015001900A1 CL 2015001900 A1 CL2015001900 A1 CL 2015001900A1 CL 2015001900 A CL2015001900 A CL 2015001900A CL 2015001900 A CL2015001900 A CL 2015001900A CL 2015001900 A1 CL2015001900 A1 CL 2015001900A1
Authority
CL
Chile
Prior art keywords
vaccines
higher density
carbohydrate antigen
saponin adjuvant
new
Prior art date
Application number
CL2015001900A
Other languages
English (en)
Inventor
Han Lee Wei
Wang Nan-Hsuan
Chang Chung-Hao
Hsieh Yih-Huang
Der Tony Yu Cheng
Wang Cheng-Chi
Lin Yu-Hsin
lin Yu-chen
Chen I-Ju
Original Assignee
Obi Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obi Pharma Inc filed Critical Obi Pharma Inc
Publication of CL2015001900A1 publication Critical patent/CL2015001900A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/256—Polyterpene radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCION PROPORCIONA VACUNAS QUE COMPRENDEN ANTIGENO CARBOHIDRATO CONJUGADO A UNA TOXINA DIFTÉRICA (DT) COMO PROTEINA PORTADORA, EN LAS QUE LA PROPORCION DEL NUMERO DE MOLÉCULAS DE ANTIGENO CARBOHIDRATO CON RESPECTO AL DE MOLÉCULAS DE PROTEINA PORTADORA ES SUPERIOR A 5:1. EN EL PRESENTE DOCUMENTO, TAMBIÉN SE DESVELA UN NUEVO ADYUVANTE DE SAPONINA Y MÉTODOS DE INHIBICIÓN DE CÉLULAS CANCEROSAS MEDIANTE LA ADMINISTRACION DE UNA CANTIDAD EFICAZ DE LA VACUNA DESVELADA EN EL PRESENTE DOCUMENTO.
CL2015001900A 2013-01-04 2015-07-03 Vacunas con mayor densidad de antigeno carbohidrato y nuevo adyuvante de saponina. CL2015001900A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361748880P 2013-01-04 2013-01-04

Publications (1)

Publication Number Publication Date
CL2015001900A1 true CL2015001900A1 (es) 2016-02-12

Family

ID=51062556

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2015001900A CL2015001900A1 (es) 2013-01-04 2015-07-03 Vacunas con mayor densidad de antigeno carbohidrato y nuevo adyuvante de saponina.
CL2015001902A CL2015001902A1 (es) 2013-01-04 2015-07-03 Vacunas con mayor densidad de antigeno carbohidrato y nuevo adyuvante de saponina (divisional).

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2015001902A CL2015001902A1 (es) 2013-01-04 2015-07-03 Vacunas con mayor densidad de antigeno carbohidrato y nuevo adyuvante de saponina (divisional).

Country Status (16)

Country Link
US (2) US10517936B2 (es)
EP (2) EP2941436B1 (es)
JP (2) JP6359561B2 (es)
KR (2) KR102084301B1 (es)
CN (2) CN111499679B (es)
AU (2) AU2014203977B2 (es)
CA (2) CA2897084C (es)
CL (2) CL2015001900A1 (es)
ES (1) ES2843509T3 (es)
IL (2) IL239785B (es)
PH (1) PH12015501519A1 (es)
RU (1) RU2015131033A (es)
SG (1) SG11201505301XA (es)
TW (2) TWI572356B (es)
WO (1) WO2014107652A2 (es)
ZA (1) ZA201504813B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10517936B2 (en) 2013-01-04 2019-12-31 OBI Pharma., Inc. Vaccines with higher carbohydrate antigen density and novel saponin adjuvant

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015032713B1 (pt) 2013-09-17 2023-03-21 Obi Pharma, Inc Composto, composição farmacêutica, uso de uma quantidade terapeuticamente efetiva da composição farmacêutica, e uso do composto
JP2017518958A (ja) 2014-03-19 2017-07-13 マッカイ メディカル ファウンデイション ザ プレスビテリアン チャーチ イン タイワン マッカイ メモリアル ホスピタルＭａｃｋａｙ Ｍｅｄｉｃａｌ Ｆｏｕｎｄａｔｉｏｎ Ｔｈｅ Ｐｒｅｓｂｙｔｅｒｉａｎ Ｃｈｕｒｃｈ Ｉｎ Ｔａｉｗａｎ Ｍａｃｋａｙ Ｍｅｍｏｒｉａｌ Ｈｏｓｐｉｔａｌ 免疫原性グリコペプチドに対する抗体、それを含む組成物、及びそれらの使用
TWI745275B (zh) * 2014-09-08 2021-11-11 中央研究院 使用醣脂激活人類ｉＮＫＴ細胞
US20170348414A1 (en) * 2014-09-15 2017-12-07 Wayne State University Novel synthetic anticancer, antifungal, and antibacterial vaccines
KR102702705B1 (ko) * 2014-09-15 2024-09-04 오비아이 파머 인코퍼레이티드 면역원성/치료적 당접합체 조성물 및 그의 용도
US10935544B2 (en) 2015-09-04 2021-03-02 Obi Pharma, Inc. Glycan arrays and method of use
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
BR112018070097A2 (pt) 2016-03-29 2019-02-12 Obi Pharma, Inc. anticorpo, hibridoma, composição farmacêutica, método para tratar câncer em um indivíduo, método para inibir a proliferação de células cancerígenas, método para diagnosticar o câncer em um indivíduo, método para tratar um paciente humano, método para fazer imagens de um indivíduo, conjugado de fármaco-anticorpo (adc), método para tratar câncer, anticorpo biespecífico e método para preparar uma população de anticorpos homogêneos
KR20230110820A (ko) 2016-04-22 2023-07-25 오비아이 파머 인코퍼레이티드 글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에의한 암 면역요법
CN110072545A (zh) 2016-07-27 2019-07-30 台湾浩鼎生技股份有限公司 免疫原性/治疗性聚糖组合物及其用途
US11643456B2 (en) 2016-07-29 2023-05-09 Obi Pharma, Inc. Human antibodies, pharmaceutical compositions and methods
TWI822055B (zh) 2016-11-21 2023-11-11 台灣浩鼎生技股份有限公司 共軛生物分子、醫藥組成物及方法
WO2019217951A1 (en) * 2018-05-11 2019-11-14 Obi Pharma Inc. Method for predicting human immune response
TW202504930A (zh) 2018-06-27 2025-02-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法
CN114805454B (zh) * 2021-01-21 2023-07-18 中国科学院生态环境研究中心 α-半乳糖神经酰胺类化合物及其制备方法和用途
CN114259559B (zh) * 2021-12-28 2024-03-19 天津科技大学 一种含有α-GalCer内源性佐剂的合成肿瘤疫苗
CN114306586A (zh) * 2022-01-04 2022-04-12 天津科技大学 基于tf抗原和壳寡糖内源性佐剂的肿瘤疫苗、方法和应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5332583A (en) 1987-11-24 1994-07-26 Connaught Laboratories Limited Vaccine containing genetically-detoxified pertussis holotoxin
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5221618A (en) 1987-11-24 1993-06-22 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5244657A (en) 1987-11-24 1993-09-14 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
ATE280235T1 (de) 1993-03-05 2004-11-15 Wyeth Corp Plasmid zur herstellung von crm-protein und diphtherie-toxin
US6544952B1 (en) * 1994-03-15 2003-04-08 Sloan-Kettering Institute For Cancer Research Synthesis of glycoconjugates of the globo-H epitope and uses thereof
TR199701547T1 (xx) 1995-06-07 1998-03-21 Smithkline Beecham Biologicals S.A. Polisakarit antijen protein e�leni�i i�eren a��.
KR19990022680A (ko) * 1995-06-23 1999-03-25 장 스테판느 폴리사카라이드 항원-담체 단백질 콘쥬게이트 및유리 담체단백질을 포함하는 백신
US6231859B1 (en) 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
DE69828507T2 (de) 1997-05-20 2006-01-05 Galenica Pharmaceuticals, Inc. Triterpene-saponin analoga mit adjuvans und immunostimulierender wirkung
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
DE10130545A1 (de) 2001-06-25 2003-01-09 Bosch Gmbh Robert Verfahren zum Betrieb einer Klimaanlage
JP2004534088A (ja) 2001-07-06 2004-11-11 スローン−ケッタリング・インスティテュート・フォア・キャンサー・リサーチ 癌のための多価コンジュゲートワクチン
US20060210555A1 (en) * 2001-12-21 2006-09-21 Antigenics, Inc. Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
US20060035267A1 (en) 2003-04-09 2006-02-16 Livingston Philip O Optimal polyvalent vaccine for cancer
CA2531023C (en) 2003-07-04 2013-04-30 Institut Pasteur Glycoconjugates and their use as potential vaccines against infection by shigella flexneri
GB0323965D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
AU2006210660B2 (en) 2005-02-01 2011-12-01 Morphosys Ag Libraries and methods for isolating antibodies
EP2144594A4 (en) 2007-04-13 2012-12-05 Academia Sinica ALPHA-GALACTOSYL CERAMIDE ANALOGUES AND THEIR USE IN IMMUNOTHERAPIES
US8324742B2 (en) * 2008-04-01 2012-12-04 Texas Instruments Incorporated Alignment mark for opaque layer
KR102256410B1 (ko) 2008-04-08 2021-05-26 슬로안-케테링인스티튜트퍼캔서리서치 트리테르펜 사포닌, 그의 합성 방법, 및 그의 용도
AU2009268937A1 (en) 2008-06-16 2010-01-14 Aj Park Compositions for inducing immune responses specific to Globo H and SSEA3 and uses thereof in cancer treatment
US7928077B2 (en) 2008-07-11 2011-04-19 Academia Sinica Alpha-galactosyl ceramide analogs and their use as immunotherapies
KR101677279B1 (ko) * 2009-06-16 2016-11-29 아카데미아 시니카 신규한 당지질 애주번트를 갖는 ｇｌｏｂｏ ｈ 및 관련 항암 백신
CA2801922A1 (en) * 2010-06-11 2011-12-15 Sloan-Kettering Institute For Cancer Research Multivalent glycopeptide constructs and uses thereof
WO2013142245A1 (en) 2012-03-23 2013-09-26 Memorial Sloan-Kettering Cancer Center Potentiating antibody-induced complement-mediated cytotoxicity via pi3k inhibition
CN111499679B (zh) * 2013-01-04 2021-07-06 台湾浩鼎生技股份有限公司 具有较高碳水化合物抗原密度的疫苗及新颖皂素佐剂
ITMI20130142A1 (it) 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
CN104693305A (zh) 2013-12-04 2015-06-10 苏州中赢医疗科技有限公司 一种抗人鞘糖脂Globo-H单克隆抗体、其制备方法及应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10517936B2 (en) 2013-01-04 2019-12-31 OBI Pharma., Inc. Vaccines with higher carbohydrate antigen density and novel saponin adjuvant
US11752204B2 (en) 2013-01-04 2023-09-12 Obi Pharma Inc. Vaccines with higher carbohydrate antigen density and novel saponin adjuvant

Also Published As

Publication number Publication date
WO2014107652A2 (en) 2014-07-10
JP6781204B2 (ja) 2020-11-04
KR20180053599A (ko) 2018-05-23
AU2017200312B2 (en) 2018-05-17
KR20150111941A (ko) 2015-10-06
JP2016504385A (ja) 2016-02-12
SG11201505301XA (en) 2015-08-28
EP2941436A4 (en) 2016-07-27
IL239785A0 (en) 2015-08-31
CA2897084A1 (en) 2014-07-10
EP2941436A2 (en) 2015-11-11
CA3044471A1 (en) 2014-07-10
JP6359561B2 (ja) 2018-07-18
HK1213266A1 (zh) 2016-06-30
TW201718004A (zh) 2017-06-01
US10517936B2 (en) 2019-12-31
ES2843509T3 (es) 2021-07-19
AU2014203977B2 (en) 2016-11-17
EP2941436B1 (en) 2020-12-02
KR101806370B1 (ko) 2017-12-07
CL2015001902A1 (es) 2016-02-12
US20150328299A1 (en) 2015-11-19
RU2015131033A (ru) 2017-02-09
BR112015016381A2 (pt) 2017-07-11
TWI572356B (zh) 2017-03-01
AU2017200312A1 (en) 2017-02-02
TWI611810B (zh) 2018-01-21
KR102084301B1 (ko) 2020-03-03
TW201429488A (zh) 2014-08-01
IL258728A (en) 2018-06-28
CA2897084C (en) 2019-07-16
ZA201504813B (en) 2017-11-29
PH12015501519A1 (en) 2016-04-18
CN111499679B (zh) 2021-07-06
CA3044471C (en) 2021-05-11
JP2018141021A (ja) 2018-09-13
CN105026413B (zh) 2020-04-24
US20200061169A1 (en) 2020-02-27
IL258728B (en) 2019-07-31
CN111499679A (zh) 2020-08-07
IL239785B (en) 2018-05-31
AU2014203977A1 (en) 2015-07-09
CN105026413A (zh) 2015-11-04
US11752204B2 (en) 2023-09-12
EP3792272A1 (en) 2021-03-17
WO2014107652A3 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
CL2015001900A1 (es) Vacunas con mayor densidad de antigeno carbohidrato y nuevo adyuvante de saponina.
IL282215A (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AR118725A2 (es) Vectores para expresión de antígenos asociados a próstata
MX2022014125A (es) Anticuerpos y conjugados de los mismos.
MX2015013203A (es) Conjugados de anticuerpo - farmaco.
MX2018007627A (es) Vacuna contra el virus del zika.
MX2021005131A (es) Polipeptidos que administran epitopos de cmh de clase i.
CU20160101A7 (es) Inmunoglobulina con fab en tándem
CL2019001745A1 (es) Conjugados anticuerpo droga para ablacion de celulas madre hematopoyeticas.
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
CL2017000170A1 (es) Conjugados de fármacos con anticuerpos anti-cdh6
MX2017017079A (es) Sistema de administracion dirigida de principio activo celular.
UY35399A (es) Conjugados de fármacos con anticuerpos
AR101455A1 (es) Molécula portadora
MX2016002166A (es) Anticuerpos.
MX372965B (es) Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.
MX378368B (es) Receptores de antigeno y usos de los mismos.
BR112015018270A2 (pt) composições que compreendem 15-ohepa e métodos de uso das mesmas
BR112018015893A2 (pt) vacinas de câncer e métodos de tratamento usando as mesmas
AR090668A1 (es) Anticuerpo anti-adamts-5, derivados y usos del mismo
MX2015013832A (es) Composicion de vacuna y metodo de uso.
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
UA116697C2 (uk) Композиція для запобігання зараженню видами роду mycoplasma
MX2019004371A (es) Anticuerpos que se unen a la proteina de envoltura del virus zika y usos de los mismos.
AR096123A1 (es) Composiciones y procedimientos para inducir tolerancia inmunitaria a las proteínas factores de coagulación